Ambalal Sarabhai Enterprises Ltd vs Sanofi Consumer Healthcare India Ltd Stock Comparison
Ambalal Sarabhai Enterprises Ltd vs Sanofi Consumer Healthcare India Ltd Stock Comparison
Last Updated on: May 18, 2026
Key Highlights
The Latest Trading Price of Ambalal Sarabhai Enterprises Ltd is ₹ 32.34 as of 15 May 15:30
. The P/E Ratio of Ambalal Sarabhai Enterprises Ltd changed from 4.6 on March 2021 to 54.8 on March 2025 . This represents a CAGR of 64.14% over 5 yearsThe P/E Ratio of Sanofi Consumer Healthcare India Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Ambalal Sarabhai Enterprises Ltd changed from ₹ 135.26 crore on March 2021 to ₹ 268.6 crore on March 2025 . This represents a CAGR of 14.71% over 5 yearsThe Market Cap of Sanofi Consumer Healthcare India Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Ambalal Sarabhai Enterprises Ltd for the Dec '25 is ₹ 54.76 crore as compare to the Sep '25 revenue of ₹ 46.07 crore. This represent the growth of 18.86% The revenue of Sanofi Consumer Healthcare India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Ambalal Sarabhai Enterprises Ltd for the Dec '25 is ₹ 6.02 crore as compare to the Sep '25 ebitda of ₹ 1.98 crore. This represent the growth of 204.04% The ebitda of Sanofi Consumer Healthcare India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Ambalal Sarabhai Enterprises Ltd changed from ₹ 0.35 crore to ₹ 3.64 crore over 7 quarters. This represents a CAGR of 281.21%
The net profit of Sanofi Consumer Healthcare India Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0%
The Dividend Payout of Ambalal Sarabhai Enterprises Ltd changed from 0 % on March 2021 to 0 % on December 2024 . This represents a CAGR of 0.0% over 7 yearsThe Dividend Payout of Sanofi Consumer Healthcare India Ltd changed from 6.06 % on December 2023 to 69.89 % on December 2024 . This represents a CAGR of 239.60% over 2 years .
About Ambalal Sarabhai Enterprises Ltd
Ambalal Sarabhai Enterprises Limited, incorporated on June 27, 1977, houses a range of companies across multi-dimensional businesses.
It is one of the oldest pharmaceutical health care companies in India, and through its group companies it manufactures and markets pharmaceutical, molecular diagnostics, and electronics products in India and internationally.
The Company produces a range of bulk drugs, pharmaceutical preparations and electronic instruments.
Pharmaceuticals segment is engaged in manufacture of drugs and formulations.
Electronics segment is engaged in manufacture of electronics instruments and services.
In 1994, the company entered into a technical collaboration with Biobras, Brazil, to manufacture highly purified insulin injections.
During the year 1997-98, the company formed a joint venture company, namely Sarabhai Piramal Pharmaceuticals Ltd with Piramal Enterprises Ltd for marketing of certain products under trademarks being used by the company.
About Sanofi Consumer Healthcare India Ltd
Sanofi Consumer Healthcare India Limited was incorporated on May 10, 2023, as part of Sanofi's global strategy to establish a standalone Consumer Healthcare business.
This strategic move resulted in the demerger of the Consumer Healthcare business from Sanofi India Limited (SIL) into the Company through a Scheme of Arrangement, thereby creating a distinct legal entity.
The Scheme of Arrangement, which was sanctioned by the National Company Law Tribunal, Mumbai (NCLT) enabled the seamless transfer and vesting of all assets, liabilities, and operations of SIL to the Company.
Pursuant to the Scheme becoming effective, the Consumer Healthcare Division (CHC) business of Sanofi India Limited (SIL) got demerged into the Company as a going concern through the Scheme of Arrangement and became effective from June 1, 2024.
FAQs for the comparison of Ambalal Sarabhai Enterprises Ltd and Sanofi Consumer Healthcare India Ltd
Which company has a larger market capitalization, Ambalal Sarabhai Enterprises Ltd or Sanofi Consumer Healthcare India Ltd?
Market cap of Ambalal Sarabhai Enterprises Ltd is 247 Cr while Market cap of Sanofi Consumer Healthcare India Ltd is 11,180 Cr
What are the key factors driving the stock performance of Ambalal Sarabhai Enterprises Ltd and Sanofi Consumer Healthcare India Ltd?
The stock performance of Ambalal Sarabhai Enterprises Ltd and Sanofi Consumer Healthcare India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Ambalal Sarabhai Enterprises Ltd and Sanofi Consumer Healthcare India Ltd?
As of May 18, 2026, the Ambalal Sarabhai Enterprises Ltd stock price is INR ₹32.34. On the other hand, Sanofi Consumer Healthcare India Ltd stock price is INR ₹4854.5.
How do dividend payouts of Ambalal Sarabhai Enterprises Ltd and Sanofi Consumer Healthcare India Ltd compare?
To compare the dividend payouts of Ambalal Sarabhai Enterprises Ltd and Sanofi Consumer Healthcare India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.